July 28, 2014 7:33 PM ET


Company Overview of Bayer Pharma AG

Company Overview

Bayer Pharma AG is engaged in the research and development of drugs and novel therapeutics for cardiovascular and blood diseases, oncological diseases, ophthalmology, and women's healthcare. It offers prescription medicines for cardiovascular and blood diseases that include heart attack, high blood pressure, peripheral arterial occlusive disease, pulmonary hypertension, stroke, and thrombosis; oncological diseases that include breast cancer, liver cancer, non-Hodgkin lymphoma, prostate cancer, and renal cell cancer; ophthalmology that include age-related macular degeneration; hormonal contraception, endometriosis, gynecological diseases, menopausal complaints, and premenstrual dysphoric diso...

Müllerstrasse 178

Berlin,  13353


Founded in 1851

10,273 Employees


49 30 468 1111


49 30 468 15305

Key Executives for Bayer Pharma AG

Chairman of Management Board
Age: 52
Chief Financial Officer and Member of Management Board
Age: 57
Senior Vice President
Head of Specialized Therapeutics Business Area
Head of Latin American Canada Region Operations
Compensation as of Fiscal Year 2014.

Bayer Pharma AG Key Developments

arGEN-X Announces Collaboration with Bayer Pharma AG to Discover and Develop Therapeutic Antibody Candidates

arGEN-X announced the initiation of a collaboration with Bayer Pharma AG, leveraging arGEN-X's SIMPLE Antibody(TM) technology for the discovery and development of therapeutic antibodies. The collaboration centers on a novel approach to addressing complex targets across multiple therapeutic areas that are often intractable by existing antibody platforms. With this collaboration, arGEN-X will apply its SIMPLE Antibody(TM) technology to multiple targets submitted by Bayer. The parties will work together to validate human antibody leads in disease-relevant models, with Bayer being responsible for further preclinical and clinical development and commercialization of therapeutic antibody products. Under the terms of the Agreement, Bayer will pay arGEN-X an upfront technology access fee, research support and technical success-based milestones. Bayer will also pay clinical, regulatory and product sales-based milestones as antibody programs progress through clinical development and registration.

Bayer HealthCare Receives MHLW Approval for Macular Edema Drug

Bayer HealthCare has received approval from the Ministry of Health, Labour and Welfare, or MHLW, for EYLEA for the treatment of macular edema secondary to central retinal vein occlusion, or CRVO. EYLEA has also been approved in Europe for the treatment of visual impairment due to macular edema secondary to CRVO as well as in the US and in selected countries in Asia and Latin America for the treatment of macular edema following CRVO.

Bayer Pharma AG Presents at BioJapan 2013 World Business Forum, Oct-09-2013

Bayer Pharma AG Presents at BioJapan 2013 World Business Forum, Oct-09-2013 . Venue: Pacifico Yokohama, Yokohama, Japan.

Similar Private Companies By Industry

Company Name Region
CREATiS GmbH Europe
Novartis Pharma GmbH Europe
NOXXON Pharma AG Europe
BioNTech AG Europe
Himko Pharma GmbH Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Bayer Pharma AG, please visit www.bayerpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.